Glenmarks novel monoclonal antibody GBR 830 to enter phase II clinical studies
GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease Glenmark Pharmaceuticals GBR 830, a novel monoclonal antibody has completed clinical phase I dosing. GBR 830 is an antagonist of OX40, a costimulatory receptor expressed on T cells mediating T cell activation [] Glenmarks novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europ
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 03, 2015 titled "Glenmarks novel monoclonal antibody GBR 830 to enter Phase 2 clinical studies in Atopic Dermatitis and Celiac Disease in US and Europe". AGM on September 22, 2015
Glenmark Pharmaceuticals Ltd has informed BSE that the 37th Annual General Meeting (AGM) of the Company will be held on September 22, 2015. Fixes Book Closure for Dividend & AGM
Glenmark Pharmaceuticals Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from September 14, 2015 to September 22, 2015 (both days inclusive) for the purpose of Payment of Dividend & 37th Annual General Meeting (AGM) of the Company to be held on September 22, 2015.The dividend, if approved by the Shareholders at the ensuing Annual General Meeting will be paid on or before October 12, 2015. Glenmark expects 4 to 6 new product approvals from US FDA in this fiscal
Glenmark Pharmaceuticals Ltd is expecting approval for four to six new products from the US Food and Drug Administration during the second half of current financial year. Responding to a...
Glenmark receives USFDA nod for oral contraceptive drug
Glenmark said it plans to commence shipping of drospirenone and ethinyl Estradiol tablets immediately Glenmark Pharmaceuticals receives ANDA approval for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg
Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated August 19, 2015 titled "Glenmark Pharmaceuticals receives ANDA approval for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg". MSCI rejig: Glenmark, IB Housing gain
India is expected to receive $254-mn worth of inflows on MSCI rejig, said foreign brokerage HSBC Securities in a research note. Glenmark Pharmaceuticals hits record high on inclusion in MSCI index
The stock has surged by 12% to Rs 1,184, also its record high on the National Stock Exchange, in early morning trades. Glenmark: Street looking at positive surprises from the US
Glenmark's June quarter performance was in line with most analyst estimates but it missed a few because of cross-currency headwinds, which lead to lower than expected sales from Rest of the World and Europe.